Novelix Pharmaceuticals files SEBI SAST disclosure for share acquisition by Vupparapalli Chandrasekhar Reddy & others

What Novelix Pharmaceuticals announced

On 13 July 2026 Novelix Pharmaceuticals Ltd (BSE: 536565) submitted a disclosure under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011. The notice informs the market that Vupparapalli Chandrasekhar Reddy and other unnamed parties have acquired a substantial block of Novelix shares.

"The Exchange has received the disclosure under Regulation 29(2) of SEBI (SAST) Regulations, 2011 for Vupparapalli Chandrasekhar Reddy & Others."

The filing does not provide further quantitative details such as the number of shares purchased, the percentage of voting rights acquired, or the consideration paid.

Details of the Regulation 29(2) filing

Regulation 29(2) mandates that any person or group acquiring 1 % or more of the voting power of a listed entity must promptly disclose the acquisition to the stock exchange. The purpose is to ensure transparency and give existing shareholders timely information about potential changes in control.

In this case, the acquirer is identified only as Vupparapalli Chandrasekhar Reddy together with "others". The filing does not list the names of the additional parties, nor does it disclose whether the acquisition was made in a single transaction or over a period of time.

Key facts at a glance

Why this matters for investors

The disclosure signals that a potentially influential shareholder has entered the shareholding pattern of Novelix. While the exact size of the stake is unknown, any acquisition crossing the 5 % threshold would trigger a mandatory open‑offer under SEBI’s takeover code, potentially diluting existing shareholders. Even below that level, a sizable block can affect voting dynamics, board composition, and strategic direction. Investors should monitor subsequent filings for updates on the exact share percentage and any related open‑offer or shareholder‑approval requirements.

Conclusion

Novelix Pharmaceuticals has complied with SEBI’s disclosure requirements by reporting a substantial share purchase by Vupparapalli Chandrasekhar Reddy and associates. The filing does not reveal the magnitude of the stake or any immediate operational impact. Further disclosures are expected if the acquirers cross regulatory thresholds that would obligate an open offer or require shareholder approval.